focus -WSS

focus

author：entertainment 2025-08-12 09:11:03 - browse：35266

Erik Tokat -- biotech JPM coverage from STAT — Eric Tokat is co-president of investment banking at Centerview Partners. Courtesy Centerview Partners

SAN FRANCISCO — Eric Tokat, biotech’s most prolific dealmaker, believes 2024 will be another strong year for acquisitions, driven by Big Pharma’s need to restock pipelines with medicines that can generate sales in the coming years.

That’s not idle speculation. It’s perhaps as close to a guarantee one can get in biotech. Last year, Tokat’s advisory firm, Centerview Partners, was involved in 19 of the 23 biotech transactions valued at $1 billion or more. Two more acquisitions of Centerview clients — Harpoon Therapeutics and Ambrx Biopharma — were announced Monday morning.

“I’m not sure if we’re going to have 23 deals or 25 deals, but I think it’s going to be a good year,” said Tokat, speaking to STAT over coffee on the sidelines of the J.P. Morgan Healthcare Conference.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： After affirmative action ruling, medical educators look to 'holistic review'
Next article： Why did Pfizer dish out millions for a Super Bowl ad?

WSS

FDA approves RSV monoclonal antibody for infants, toddlers

Rescued Australian man who was adrift 3 months in Pacific with dog 'grateful' to be alive

Group opposing PBM reform sets lobbying record

Medicare to cover more brain scans for Alzheimer’s patients

Medicare to cover more brain scans for Alzheimer’s patients

WHO calls for emergency meeting on new China virus, as cases spread

Wikipedia

focus

knowledge

In Memoriam: Notable people who died in 2023

How Medicaid coverage policies for immigrants impact new moms

Activists slam private health insurers over coverage restrictions

Custom gene therapy hints at new path for rare disease treatments

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

PhRMA lawsuit over Medicare drug price negotiation tossed

Activists slam private health insurers over coverage restrictions

Group opposing PBM reform sets lobbying record

Cancer drug shortages should be causing more outrage

Gilead might be held responsible for not developing a drug

hotspot

What we’ve learned from the Aduhelm mess

FDA approves RSV monoclonal antibody for infants, toddlers

AI can’t replace a physician’s gut feeling

Readout LOUD podcast: How biotech is using artificial intelligence

A disappointing year of Humira biosimilars

Private equity deals in Medicare Advantage declines

focus

hotspot

leisure time

explore